DUBLIN–(BUSINESS WIRE)–The “Cholera – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest Pharmaceutical and Healthcare disease pipeline guide Cholera – Pipeline Review, H2 2019, provides an overview of the Cholera (Infectious Disease) pipeline landscape.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Cholera – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 6 and 2 molecules, respectively.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Report Coverage
- Cholera – Overview
- Cholera – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cholera – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cholera – Companies Involved in Therapeutics Development
- Akthelia Pharmaceuticals Ltd
- Beijing Minhai Biotechnology Co Ltd
- Napo Pharmaceuticals Inc
- Cholera – Drug Profiles
- AKT-10082 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera (trivalent) vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera (whole cell) vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera [serotypes O1 + O139] (bivalent) vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera [strain O1/El/Tor/Ogawa] vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- cholera vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cholvax – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- crofelemer DR – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- gram-negative bacterial infections vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- IMSUTMR-1501 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LB-2 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Peptide for Cholera and Guillain-Barre Syndrome – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules for Bacterial Infections – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Cholera – Dormant Projects
- Cholera – Discontinued Products
- Cholera – Product Development Milestones
- Featured News & Press Releases
- Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks
- Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine
- Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qlkrjh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
